Replies to post #252200 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Cash the spike of efficacy similar to that seen in the first few weeks of the P2a AD trial?

[TTTav66]

The rationale for the 14 week duration is specifically related to the choice of using the CDR Continuity of Attention as the primary efficacy trial endpoint. In pretty much every company presentation for the past year, they have highlighted their belief that CogState IDN data from the Alz 2A trial should be predictive of what will be seen in the CDR measure.

See slides 23-25 here: https://www.anavex.com/wp-content/uploads/2020/02/Anavex-Presentation-February-2020.pdf

[Doc328]

Agree with TTT. Also, when additional data from the rivastigmine phase 3 study with 500 patients was evaluated, the CDR-COA test (primary endpoint) was significant at 16 weeks. If PDD data is good, I would expect the phase 3 to be 24-26 weeks, like the rivastigmine study.